Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 6/20 | 0.51 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.51 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 4/20 | 0.48 |
| ▸ | MMP2 | P08253 | 2/20 | 0.48 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.45 |
| ▸ | ITGAV | P06756 | 2/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 3/20 | 0.45 |
| ▸ | MMP13 | P45452 | 3/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8248902 | 1.00 | ITGB1 (0.51) | ITGB1ITGA4ITGA2MMP9MMP2 | |
| SCHEMBL8238744 | 0.92 | MMP9 (0.47) | ITGB1ITGA4ITGA2MMP9MMP2 | |
| SCHEMBL6151068 | 0.90 | ITGB1 (0.58) | ITGB1ITGA4ITGA2MMP9ITGA5 | |
| SCHEMBL6401233 | 0.90 | ITGB1 (0.58) | ITGB1ITGA4ITGA2MMP9ITGA5 | |
| SCHEMBL4253017 | 0.88 | ITGB1 (0.56) | ITGB1ITGA4ITGA2MMP9MMP2 | |
| SCHEMBL8245244 | 0.88 | ITGB1 (0.56) | ITGB1ITGA4ITGA2MMP9MMP2 | |
| SCHEMBL8248228 | 0.88 | ITGB1 (0.57) | ITGB1ITGA4ITGA2MMP9MMP2 | |
| SCHEMBL4258002 | 0.88 | ITGB1 (0.57) | ITGB1ITGA4ITGA2MMP9MMP2 | |
| SCHEMBL4256087 | 0.86 | MMP9 (0.48) | ITGB1ITGA4ITGA2MMP9MMP2 | |
| SCHEMBL8239095 | 0.86 | MMP9 (0.48) | ITGB1ITGA4ITGA2MMP9MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258159-B2 | Inhibitors of the α2β1/GPIa-IIa integrin | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-09-04 | — | — | US | claimed |
| US-20090233968-A1 | INHIBITORS OF THE ALPHA2BETA1/GPIa-IIA INTEGRIN | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-09-17 | — | — | US | claimed |
| EP-1898940-A1 | INHIBITORS OF THE ALPHA2BETA 1/GPIA-IIA INTEGRIN | The Trustees of The University of Pennsylvania (US) | 2008-03-19 | — | — | EP | claimed |
| WO-2006133338-A1 | INHIBITORS OF THE α2β1/GPIa-IIa INTEGRIN | THE TRUSTEES OF THE UNIVERSITY OF PENNESYLVANIA (US) | 2006-12-14 | — | — | WO | claimed |
| US-8258159-B2 | Inhibitors of the α2β1/GPIa-IIa integrin | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-09-04 | — | — | US | disclosed |
| US-20090233968-A1 | INHIBITORS OF THE ALPHA2BETA1/GPIa-IIA INTEGRIN | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-09-17 | — | — | US | disclosed |
| EP-1898940-A1 | INHIBITORS OF THE ALPHA2BETA 1/GPIA-IIA INTEGRIN | The Trustees of The University of Pennsylvania (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006133338-A1 | INHIBITORS OF THE α2β1/GPIa-IIa INTEGRIN | THE TRUSTEES OF THE UNIVERSITY OF PENNESYLVANIA (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233968-A1 | INHIBITORS OF THE ALPHA2BETA1/GPIa-IIA INTEGRIN | ITGA2B, ITGB2, ITGA2 | ITGB1 4/4885ITGA4 17/4885ITGA2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.